Indivior PLC stock (GB00BYZ0C031): opioid treatment specialist updates investors after restating 2023 results

Indivior PLC has restated its 2023 financial results and updated investors on governance and US listing plans, keeping attention on the opioid treatment group’s strategy and outlook.

Indivior PLC, the specialty pharmaceutical group focused on treatments for opioid use disorder, has drawn investor attention after restating its 2023 results and issuing updated disclosures on governance and its US listing structure in April 2025, according to company filings and announcements published that month, as reported by Indivior investor update as of 04/18/2025 and coverage from Reuters as of 04/22/2025.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior
• Sector/industry: Pharmaceuticals / addiction treatment
• Headquarters/country: United Kingdom
• Core markets: United States, Europe and selected international markets
• Key revenue drivers: Medications for opioid use disorder and related psychiatric conditions
• Home exchange/listing venue: Nasdaq (ticker: INDV) and London Stock Exchange
• Trading currency: USD on Nasdaq, GBP in London

Indivior PLC: core business model

Indivior PLC focuses on developing and commercializing medications aimed primarily at opioid use disorder and other addiction-related conditions, positioning itself as a specialist in an area that remains a significant public health challenge in the United States. The company’s portfolio centers on formulations of buprenorphine, a partial opioid agonist used to manage dependence, along with newer long-acting products intended to improve adherence and outcomes for patients.

The business model combines proprietary drug development with a commercial infrastructure that targets addiction treatment providers, clinics and healthcare systems, especially in the US, where opioid use disorder prevalence and treatment funding have created a sizable market. Indivior generates most of its revenue from prescription sales rather than from one-time milestones, giving it a recurring revenue profile that depends on formulary access, reimbursement and physician adoption.

Alongside its commercial portfolio, Indivior invests in clinical research to expand indications and support lifecycle management of its core brands. This includes work on long-acting injectable therapies, improved delivery mechanisms and potential treatments addressing co-occurring mental health conditions. The company’s strategy emphasizes evidence-based medicine and regulatory engagement to maintain and expand label claims in its key geographies.

Intellectual property protection and market exclusivity remain important components of Indivior’s model, particularly in the US, where brand-to-generic transitions can rapidly affect pricing and volumes. The company manages patent portfolios, engages in litigation when necessary and negotiates with payers to balance access and profitability, while also navigating the complex policy environment surrounding opioid-related products.

Main revenue and product drivers for Indivior PLC

Historically, Indivior’s revenue has been heavily concentrated in the United States, where opioid use disorder treatment is widely reimbursed through public and private payers. The company’s leading products include sublingual and long-acting injectable buprenorphine-based therapies, which clinicians use as part of medication-assisted treatment programs to reduce cravings and withdrawal symptoms. These therapies are prescribed in office-based settings and specialized addiction centers across the country.

In its 2023 annual report, published in March 2024, Indivior reported that US net revenue continued to account for the majority of its sales, reflecting the scale of the American opioid epidemic and the established reimbursement landscape for medication-assisted treatment, according to the company’s 2023 results release dated March 7, 2024, as summarized by Indivior annual report as of 03/07/2024. Growth was supported by adoption of long-acting injectables, which can offer monthly dosing and have become an important driver of prescription trends.

Outside the US, Indivior also markets its opioid use disorder treatments in Europe, Canada and other international territories, though these regions contribute a smaller share of total revenue. Local pricing and reimbursement dynamics, treatment guidelines and the availability of alternative therapies influence uptake in each market. The company has been working to secure broader reimbursement and guidelines inclusion in several European countries to gradually expand its non-US revenue base.

The product mix also includes legacy formulations that face generic competition, particularly older sublingual products. Managing the transition from these legacy brands to newer, differentiated offerings is a key commercial priority, as it affects both pricing power and volume stability. Indivior’s strategy has been to focus promotion on higher-value, long-acting and innovative treatments while maintaining presence in segments where it can compete effectively on value and support.

Beyond opioids, Indivior has been exploring adjacent therapeutic areas where its expertise in addiction and behavioral health may be applicable. This includes potential treatments targeting alcohol use disorder and other conditions that often co-occur with opioid dependency. While these programs are at earlier stages compared with the company’s core portfolio, they provide optionality for future revenue diversification.

Why Indivior PLC matters for US investors

For US investors, Indivior is directly exposed to the American healthcare system and policy environment around opioid use disorder. The company’s products are used widely across US treatment settings, and shifts in federal or state funding, prescribing guidelines or reimbursement policies can have a meaningful impact on its financial performance. This makes the stock sensitive to public health and regulatory developments that go beyond traditional pharmaceutical pricing debates.

The Nasdaq listing provides US-based investors with straightforward access to the shares in US dollars, complementing the company’s primary listing in London. Trading volumes on US venues, along with Indivior’s interactions with US regulators and payers, contribute to its visibility on the US market. For investors following the broader healthcare and biotech sectors, Indivior offers exposure to a niche of the pharmaceutical industry focused on addiction and mental health, which has been gaining attention in policy discussions and funding priorities.

At the same time, the company operates within a highly scrutinized area of medicine. US investors monitor legal, compliance and reputational risks, including potential litigation related to marketing practices, safety questions around opioid-related products and evolving standards of care for addiction. These factors contribute to the risk profile of the stock and can influence valuation multiples compared with diversified pharmaceutical companies.

Conclusion

Indivior PLC occupies a specialized position in the pharmaceutical landscape with its focus on opioid use disorder and related conditions, a field of particular relevance to the United States. The company’s restated 2023 financials and subsequent investor communications have kept attention on its governance and strategic direction, while its core business continues to revolve around buprenorphine-based therapies and long-acting treatments. For market participants, the stock represents focused exposure to addiction treatment, influenced by US healthcare policy, reimbursement trends and ongoing efforts to manage the opioid crisis, all of which can affect both risks and opportunities over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.